Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
Solu-Medrone 125 mg or methylprednisolone sodium succinate for injection.
| Pharmaceutical Form |
|---|
|
Powder for injection. |
Solu-Medrone 125 mg: Methylprednisolone sodium succinate 165.8 mg equivalent to 125 mg of methylprednisolone.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Methylprednisolone |
Methylprednisolone is a synthetic glucocorticoid and a methyl derivative of prednisolone. Methylprednisolone is a potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system. |
| List of Excipients |
|---|
|
Sodium biphosphate |
Type I clear glass vial with butyl rubber plug and flip top seal.
Each vial of Solu-Medrone 125 mg contains the equivalent of 125 mg of methylprednisolone as the sodium succinate for reconstitution with 2 ml of Sterile Water for Injections.
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
PL 00057/1046
2nd February 2005
| Drug | Countries | |
|---|---|---|
| SOLU-MEDRONE | Cyprus, Ireland, Malta, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
